Carbocain Dental: Uses, Dosage & Side Effects
An amide local anesthetic solution containing mepivacaine for dental infiltration and nerve block anesthesia, formulated without a vasoconstrictor
Carbocain dental is a local anesthetic solution containing mepivacaine hydrochloride 30 mg/ml (3%), used exclusively in dental practice to produce regional anesthesia for dental procedures. Mepivacaine belongs to the amide class of local anesthetics and works by reversibly blocking sodium channels in nerve fibers, preventing the transmission of pain signals. Uniquely among dental local anesthetics, the 3% mepivacaine formulation does not contain a vasoconstrictor (such as epinephrine), which makes it particularly valuable for patients with cardiovascular conditions, endocrine disorders, or those taking medications that may interact adversely with vasoconstrictors. The anesthetic onset is rapid (1–4 minutes), with pulpal anesthesia lasting approximately 20 minutes for infiltration and up to 40–60 minutes for nerve blocks.
Quick Facts: Carbocain Dental
Key Takeaways
- Carbocain dental contains mepivacaine hydrochloride 3% (30 mg/ml) and is a prescription-only local anesthetic specifically designed for dental infiltration and nerve block procedures, administered by dental professionals.
- This formulation does not contain a vasoconstrictor (epinephrine/adrenaline), making it safer for patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, pheochromocytoma, or those on interacting medications such as tricyclic antidepressants or non-selective beta-blockers.
- Mepivacaine has a rapid onset of action (1–4 minutes) with shorter duration of anesthesia compared to vasoconstrictor-containing formulations, providing pulpal anesthesia for approximately 20 minutes (infiltration) and soft tissue anesthesia for 2–3 hours.
- The maximum recommended dose is 4.4 mg/kg body weight in adults (not exceeding 300 mg total) and 3 mg/kg in children, making careful dose calculation essential, particularly in pediatric and elderly patients.
- Common side effects are generally mild and related to the injection technique; serious systemic toxicity involving the central nervous system or cardiovascular system is rare but requires immediate medical intervention if it occurs.
What Is Carbocain Dental and What Is It Used For?
Carbocain dental contains the active substance mepivacaine hydrochloride, a member of the amide class of local anesthetics. Mepivacaine was first synthesized in 1956 by chemists at AB Bofors in Sweden and was introduced into clinical dental practice in the early 1960s. It has since become one of the most widely used local anesthetics in dentistry worldwide, valued for its rapid onset, intermediate duration of action, and excellent safety profile. The 3% plain formulation (without vasoconstrictor) has particular clinical utility in situations where the addition of epinephrine is undesirable or contraindicated.
Local anesthetics work by blocking voltage-gated sodium channels in the cell membranes of peripheral nerve fibers. Under normal circumstances, when a painful stimulus is applied (such as a dental drill contacting tooth structure), sodium ions rush into the nerve cell through these channels, generating an electrical impulse (action potential) that travels along the nerve fiber to the brain, where it is perceived as pain. Mepivacaine reversibly binds to a specific receptor site within the sodium channel, preventing the influx of sodium ions and thereby blocking the generation and conduction of nerve impulses. This results in a reversible loss of sensation (anesthesia) in the area supplied by the blocked nerve, while the patient remains fully conscious.
The chemical structure of mepivacaine includes an amide bond linking the aromatic ring to the intermediate chain, which distinguishes it from the older ester-type local anesthetics (such as procaine). Amide local anesthetics are metabolized primarily in the liver by microsomal enzymes, as opposed to ester-type agents which are hydrolyzed by plasma cholinesterases. This difference has practical implications: amide-type anesthetics like mepivacaine have a much lower incidence of true allergic reactions compared to ester-type agents, and their duration of action is generally more predictable.
What distinguishes the 3% mepivacaine formulation from many other dental local anesthetic cartridges is the absence of a vasoconstrictor. Most dental local anesthetic solutions contain a small amount of epinephrine (adrenaline) or levonordefrin, which constricts blood vessels at the injection site, slowing the absorption of the anesthetic into the bloodstream and thereby prolonging its duration of action and reducing systemic toxicity. However, mepivacaine has an unusual pharmacological property among local anesthetics: it possesses inherent mild vasoconstrictive activity at clinical concentrations, rather than the vasodilating effect seen with most other local anesthetics like lidocaine. This intrinsic vasoconstriction means that mepivacaine provides clinically adequate anesthesia even without an added vasoconstrictor, although the duration is shorter than with vasoconstrictor-containing formulations.
Carbocain dental 3% is indicated for producing local anesthesia in dental practice through the following injection techniques:
- Infiltration anesthesia: Injection into the tissue near the tooth to be treated, allowing the anesthetic to diffuse through the bone to reach the dental nerves. This technique is commonly used for upper (maxillary) teeth and lower (mandibular) anterior teeth.
- Inferior alveolar nerve block (IANB): Injection near the mandibular foramen to block the inferior alveolar nerve, providing anesthesia to the lower teeth, lower lip, and chin on the injected side. This is the primary technique for anesthetizing lower posterior teeth.
- Mental and incisive nerve blocks: Injection near the mental foramen to anesthetize the premolars, canine, and incisors on the same side of the mandible.
- Other regional nerve blocks: Including long buccal nerve block, anterior superior alveolar nerve block, middle superior alveolar nerve block, posterior superior alveolar nerve block, and infraorbital nerve block, depending on the area requiring anesthesia.
The 3% plain mepivacaine formulation is particularly suitable for short dental procedures (typically under 30 minutes of pulpal anesthesia for infiltration). It is the formulation of choice when a vasoconstrictor is contraindicated, such as in patients with severe cardiovascular disease, uncontrolled hypertension, or those taking medications that may interact dangerously with epinephrine. Additionally, because the duration of soft tissue anesthesia is shorter than with vasoconstrictor-containing formulations, patients experience less prolonged numbness of the lips, tongue, and cheeks after the dental procedure, which is often preferred by patients and is particularly advantageous in pediatric dentistry to reduce the risk of self-inflicted soft tissue injury from biting.
The absence of a vasoconstrictor in Carbocain dental 3% is not a limitation but rather a specific clinical advantage. It makes this formulation the local anesthetic of choice for patients in whom vasoconstrictors are medically contraindicated, and for short procedures where prolonged soft tissue numbness is undesirable. Mepivacaine's inherent mild vasoconstrictive properties help maintain adequate clinical anesthesia even without epinephrine.
What Should You Know Before Taking Carbocain Dental?
Contraindications
Carbocain dental must not be used in the following situations:
- Known hypersensitivity: Allergy to mepivacaine or any other amide-type local anesthetic (such as lidocaine, bupivacaine, ropivacaine, articaine, or prilocaine), or to any of the excipients in the formulation. True allergic reactions to amide-type local anesthetics are extremely rare (estimated at less than 1% of all adverse reactions to local anesthetics), but when they do occur, they can be severe and life-threatening. Many reported "allergies" to local anesthetics are actually vasovagal syncope reactions, anxiety responses, or reactions to preservatives or vasoconstrictors rather than to the anesthetic agent itself.
- Severe hepatic disease: Since mepivacaine is metabolized primarily by hepatic microsomal enzymes (particularly CYP1A2 and CYP3A4), patients with severe liver disease may have significantly impaired clearance of the drug, leading to elevated plasma levels and increased risk of systemic toxicity.
- Acute porphyria: Amide-type local anesthetics, including mepivacaine, may trigger acute attacks in patients with porphyria, a group of inherited metabolic disorders affecting heme biosynthesis. These patients should be treated with alternative anesthetic approaches.
Warnings and Precautions
Accidental intravascular injection of mepivacaine can cause immediate systemic toxic reactions affecting the central nervous system (seizures, loss of consciousness) and cardiovascular system (cardiac arrhythmias, cardiac arrest). Dental practitioners must always aspirate before injection and inject slowly. Resuscitation equipment must be immediately available whenever local anesthetics are administered.
Before receiving Carbocain dental, inform your dental practitioner if you have any of the following conditions:
- Cardiovascular disease: Patients with heart block, severe bradycardia, decompensated heart failure, or recent myocardial infarction require careful evaluation before any local anesthetic is administered. Although the 3% plain formulation without vasoconstrictor has a lower cardiovascular risk profile than epinephrine-containing formulations, mepivacaine itself can still affect cardiac conduction at high plasma concentrations.
- Hepatic impairment: Patients with moderate to severe liver disease may have reduced metabolism of mepivacaine, necessitating dose reduction. The maximum dose should be carefully calculated and potentially reduced in these patients.
- Renal impairment: While mepivacaine undergoes hepatic metabolism, approximately 1–16% of the dose is excreted unchanged by the kidneys. Patients with severe renal impairment may have altered drug clearance and should be monitored.
- Epilepsy: Local anesthetics can lower the seizure threshold. Patients with epilepsy or a history of seizures may be at increased risk of CNS toxicity. Use the minimum effective dose and inject slowly.
- Myasthenia gravis: Local anesthetics may exacerbate muscle weakness in patients with myasthenia gravis. Use with caution and monitor the patient carefully.
- Cholinesterase deficiency: Although amide-type anesthetics are not primarily metabolized by cholinesterase (unlike ester-type agents), patients with atypical plasma cholinesterase may have altered responses to certain anesthetics. Inform your dentist of any known enzyme deficiencies.
- Elderly patients: Reduced hepatic blood flow and liver mass in elderly patients may result in slower metabolism of mepivacaine. Use reduced doses and monitor carefully for signs of toxicity.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your dentist before receiving Carbocain dental. Mepivacaine crosses the placental barrier and can reach the fetal circulation. While animal studies have not demonstrated teratogenic effects at clinically relevant doses, there are limited data on the use of mepivacaine in pregnant women. The American Dental Association (ADA) and the American College of Obstetricians and Gynecologists (ACOG) jointly advise that dental treatment with local anesthesia can be safely performed during pregnancy when necessary, ideally during the second trimester when organogenesis is complete and the patient is generally most comfortable.
Mepivacaine is specifically not recommended for obstetric paracervical block anesthesia. This is because the 3% concentration, combined with the highly vascular nature of the paracervical tissues, can result in rapid absorption and high fetal blood levels, potentially causing fetal bradycardia and neonatal depression. This restriction applies specifically to obstetric use and does not contraindicate the use of Carbocain dental for routine dental procedures in pregnant women when clinically indicated.
It is not fully established whether mepivacaine is excreted in human breast milk. Given the relatively short duration of action and the small doses used in dental practice, the amount of mepivacaine that might reach breast milk is expected to be negligible. However, as a precautionary measure, breastfeeding may be temporarily interrupted for a few hours after dental anesthesia if the mother is concerned. Consult your dentist or physician for personalized advice.
Children
Mepivacaine can be used in pediatric dental patients, but the dose must be carefully calculated based on body weight. Children are more susceptible to local anesthetic toxicity because they have lower body mass, higher cardiac output relative to body weight (which increases the rate of systemic absorption), and immature hepatic enzyme systems (which may slow metabolism of the drug). The maximum recommended dose of 3% mepivacaine in children is 3 mg/kg of body weight. Special attention should be paid to avoid exceeding this dose, particularly when multiple injection sites are required during the same treatment session.
An important practical consideration in pediatric patients is the risk of self-inflicted soft tissue injury (lip, tongue, or cheek biting) during the period of prolonged numbness after dental treatment. The shorter duration of soft tissue anesthesia with 3% mepivacaine plain (compared to vasoconstrictor-containing formulations) is advantageous in this regard, as it reduces the window during which accidental biting injuries can occur. Parents and caregivers should be advised to supervise the child and prevent biting or chewing until sensation has fully returned.
Driving and Operating Machinery
Carbocain dental is not expected to impair the ability to drive or operate machinery under normal circumstances. However, individual responses vary, and some patients may experience temporary dizziness, blurred vision, or drowsiness after dental anesthesia. If you experience any such effects, wait until they have completely resolved before driving or operating dangerous equipment. The numbness of the lip, tongue, or cheek may also affect speech and the ability to eat or drink safely for several hours after the procedure.
How Does Carbocain Dental Interact with Other Drugs?
Understanding the drug interaction profile of Carbocain dental is essential for safe administration. Since the 3% plain formulation does not contain a vasoconstrictor, the interaction profile is narrower than that of vasoconstrictor-containing formulations. However, several important interactions remain that dental practitioners and patients should be aware of.
Mepivacaine is metabolized in the liver primarily by cytochrome P450 enzymes CYP1A2 and CYP3A4. Drugs that significantly inhibit or induce these enzymes can alter the rate of mepivacaine clearance, potentially increasing or decreasing its plasma levels and effects. Additionally, the pharmacological effects of mepivacaine on the nervous and cardiovascular systems can interact additively or synergistically with other drugs that affect these organ systems.
| Drug Category | Examples | Interaction | Clinical Significance |
|---|---|---|---|
| Other local anesthetics | Lidocaine, articaine, bupivacaine, prilocaine | Additive systemic toxic effects | Major – Reduce total combined dose |
| Beta-blockers | Propranolol, metoprolol, atenolol | Reduced hepatic clearance of mepivacaine; additive cardiac depressant effects | Moderate – Use lower doses; monitor cardiovascular status |
| Class III antiarrhythmics | Amiodarone, sotalol | Additive cardiac conduction effects; potential for arrhythmias | Major – Use minimum effective dose; cardiac monitoring advised |
| CYP1A2 inhibitors | Fluvoxamine, ciprofloxacin, cimetidine | Inhibited hepatic metabolism of mepivacaine; elevated plasma levels | Moderate – Consider dose reduction |
| CNS depressants | Benzodiazepines, opioids, sedative antihistamines | Additive CNS depression; reduced seizure threshold | Moderate – Monitor for excessive sedation |
| Muscle relaxants | Suxamethonium, non-depolarizing agents | Potential prolongation of neuromuscular blockade | Minor – Relevant in general anesthesia settings |
| Anticoagulants | Warfarin, heparin, DOACs (rivaroxaban, apixaban) | No direct pharmacological interaction, but increased bleeding risk at injection site | Minor – Use careful injection technique; avoid nerve blocks if possible |
Major Interactions
The most clinically significant interaction is with other local anesthetics. When multiple local anesthetic agents are used during the same dental appointment (for example, if an initial injection of mepivacaine is supplemented with articaine or lidocaine), the toxic effects are additive. The total dose of all local anesthetics administered must be considered collectively when determining maximum dose limits, not just the dose of each agent individually. This is particularly important in complex dental procedures requiring multiple injection sites.
Class III antiarrhythmic agents, particularly amiodarone, pose another significant interaction risk. Both mepivacaine and class III antiarrhythmics can prolong cardiac conduction and depress myocardial function. The combination may increase the risk of bradycardia, hypotension, and cardiac arrhythmias. Patients taking these medications require careful evaluation, the use of minimum effective doses of local anesthetic, and may benefit from cardiovascular monitoring during the dental procedure.
Minor Interactions
Interactions with CNS depressant medications (benzodiazepines, opioids, and sedative antihistamines) are generally of moderate clinical significance. These drugs may enhance the central nervous system depressant effects of mepivacaine if the local anesthetic reaches the systemic circulation in sufficient quantities. This is most relevant in anxious patients who may have taken a sedative before their dental appointment, or in patients receiving conscious sedation. Dental practitioners should inquire about premedication and adjust the local anesthetic dose accordingly.
Patients taking anticoagulant or antiplatelet medications do not have a direct pharmacological interaction with mepivacaine. However, these medications increase the risk of bleeding and hematoma formation at the injection site, which can in turn increase the risk of nerve compression and prolonged or permanent nerve damage. The risk is highest with inferior alveolar nerve blocks, where the injection is given near the pterygoid venous plexus. Dental practitioners may prefer infiltration techniques over nerve blocks when possible in anticoagulated patients, and should apply firm pressure at the injection site after administration.
Because Carbocain dental 3% does not contain epinephrine or any other vasoconstrictor, it avoids the significant drug interactions associated with vasoconstrictor-containing formulations. These include potentially dangerous interactions with tricyclic antidepressants (imipramine, amitriptyline), MAO inhibitors, non-selective beta-blockers, cocaine, and certain recreational drugs. This makes Carbocain dental 3% a safer choice for patients taking these medications.
What Is the Correct Dosage of Carbocain Dental?
Carbocain dental should always be administered by a qualified dental professional using proper aspiration technique and slow injection. The dose must be individualized based on the type of procedure, the area to be anesthetized, the vascularity of the tissue, the patient's body weight, age, and general health status. The lowest dose that provides effective anesthesia should always be used.
| Patient Group | Max Dose (mg/kg) | Max Total Dose | Max Cartridges (1.8 ml) |
|---|---|---|---|
| Adults (healthy) | 4.4 mg/kg | 300 mg | 5.5 cartridges |
| Adults (medically compromised) | 2–3 mg/kg | Individualized | Individualized |
| Children (over 3 years) | 3 mg/kg | Based on weight | Based on weight |
| Elderly | 2–3 mg/kg | Individualized | Individualized |
Adults
For healthy adult patients, the maximum recommended dose of 3% mepivacaine is 4.4 mg/kg of body weight, not to exceed an absolute maximum of 300 mg per appointment. Each standard dental cartridge contains 1.8 ml of solution, which at a concentration of 30 mg/ml provides 54 mg of mepivacaine per cartridge. Therefore, for a 70 kg adult, the maximum number of cartridges is approximately 5.5 (70 kg × 4.4 mg/kg = 308 mg, capped at 300 mg = 5.5 cartridges).
The typical doses for common dental injection techniques using 3% mepivacaine are:
- Infiltration (maxillary teeth): 0.5–1.0 cartridge (27–54 mg) per tooth. Anesthesia onset within 1–2 minutes. Pulpal anesthesia duration approximately 20 minutes.
- Inferior alveolar nerve block: 1.0–1.5 cartridges (54–81 mg). Onset within 3–5 minutes. Pulpal anesthesia duration approximately 40–60 minutes.
- Mental/incisive nerve block: 0.5–1.0 cartridge (27–54 mg). Onset within 2–3 minutes. Pulpal anesthesia duration approximately 40 minutes.
- Long buccal nerve block: 0.25–0.5 cartridge (14–27 mg). Onset within 1–2 minutes.
It is critical to aspirate (pull back on the syringe plunger) before injecting to check for blood return, which would indicate accidental needle placement within a blood vessel. If blood is aspirated, the needle should be repositioned before injection. Injection should be performed slowly (a minimum of 60 seconds per cartridge is recommended) to reduce pain on injection and minimize the risk of rapid systemic absorption.
Children
In pediatric patients over 3 years of age, the maximum recommended dose of 3% mepivacaine is 3 mg/kg of body weight. Careful dose calculation based on the child's actual weight is essential, as exceeding the maximum dose in children can more easily result in systemic toxicity. As an example, for a 20 kg child, the maximum dose would be 60 mg, which corresponds to approximately 1.1 cartridges (60 mg ÷ 54 mg per cartridge = 1.1). Children under 3 years of age should generally not receive mepivacaine except under specialist supervision, as clinical data in this age group are limited.
The American Academy of Pediatric Dentistry (AAPD) emphasizes the importance of weight-based dosing calculations in children and recommends documenting the calculated maximum dose before beginning the injection. Common errors in pediatric dosing include using adult doses without weight adjustment, failing to account for multiple injection sites, and not considering the cumulative dose when additional anesthetic is needed during the procedure.
Elderly Patients
Elderly patients may have reduced hepatic function, decreased cardiac output, and altered distribution volumes that can affect the pharmacokinetics of mepivacaine. The general recommendation is to use reduced doses (2–3 mg/kg) in elderly patients and to inject slowly while monitoring for signs of toxicity. The onset of anesthesia may be slightly delayed in elderly patients due to age-related changes in nerve fiber structure, and the duration may be either prolonged (due to slower metabolism) or shortened (due to altered tissue perfusion).
Missed Dose
The concept of a missed dose does not apply to Carbocain dental, as it is a single-use medication administered by a dental professional during a specific dental procedure. It is not a medication that is taken on a regular schedule at home. If a dental appointment is missed, the anesthetic will simply be administered at the rescheduled appointment.
Overdose
Overdose with local anesthetics is a medical emergency that can affect both the central nervous system and the cardiovascular system. Systemic toxicity from mepivacaine typically follows a predictable pattern of increasing severity:
Early CNS symptoms: Lightheadedness, dizziness, tinnitus (ringing in the ears), metallic taste, perioral numbness (numbness around the mouth), visual disturbances, slurred speech, muscle twitching.
Advanced CNS symptoms: Generalized tonic-clonic seizures, followed by CNS depression, respiratory depression, and loss of consciousness.
Cardiovascular symptoms: Hypotension, bradycardia, cardiac conduction abnormalities, ventricular arrhythmias, and in severe cases, cardiovascular collapse and cardiac arrest.
If overdose is suspected, stop the injection immediately, ensure the airway is patent, administer 100% oxygen, and call emergency medical services. Seizures should be managed with benzodiazepines (midazolam or diazepam). Cardiovascular collapse may require advanced cardiac life support (ACLS) including IV fluids, vasopressors, and in cases of local anesthetic-induced cardiac arrest, the administration of 20% intravenous lipid emulsion (Intralipid), which acts as a "lipid sink" to sequester the lipophilic local anesthetic from cardiac tissue.
What Are the Side Effects of Carbocain Dental?
Like all local anesthetic agents, Carbocain dental can cause side effects, although not everyone will experience them. The side effects of dental local anesthetics can be broadly categorized into those related to the injection technique, those related to the pharmacological action of the drug, and true adverse drug reactions. Understanding these distinctions is important for appropriate management. The vast majority of adverse events reported with dental local anesthetics are psychogenic (anxiety-related) or vasovagal in nature, rather than true drug reactions.
The overall incidence of clinically significant adverse effects with mepivacaine in dental use is low. Data from decades of clinical experience and post-marketing surveillance confirm that mepivacaine is among the safest local anesthetics available for dental use when administered in appropriate doses by qualified practitioners using proper technique.
Very Common
May affect more than 1 in 10 people
- Numbness and tingling at the injection site and surrounding tissues (this is the intended therapeutic effect)
- Temporary pain or discomfort during injection
- Soft tissue numbness of the lip, tongue, or cheek lasting 2–3 hours after injection
Common
May affect up to 1 in 10 people
- Temporary swelling at the injection site
- Headache
- Dizziness or lightheadedness
- Nausea
- Tachycardia (rapid heartbeat, usually due to anxiety rather than the drug)
- Trismus (difficulty opening the mouth, particularly after inferior alveolar nerve block)
Uncommon
May affect up to 1 in 100 people
- Prolonged numbness or altered sensation (paresthesia) lasting beyond the expected duration
- Hematoma (bruising) at the injection site
- Blurred vision or diplopia (double vision, especially after posterior superior alveolar nerve block)
- Facial nerve palsy (temporary weakness of facial muscles on the affected side)
- Metallic taste
- Vasovagal syncope (fainting episode related to anxiety or pain)
Rare
May affect up to 1 in 1,000 people
- Allergic reactions (urticaria, skin rash, angioedema)
- Persistent paresthesia or dysesthesia of the lip, tongue, or chin lasting weeks to months
- Infection at the injection site
- Needle breakage (extremely rare with modern disposable needles)
Very Rare / Not Known
Frequency cannot be estimated from available data
- Anaphylaxis (life-threatening allergic reaction)
- Systemic toxicity (seizures, cardiovascular collapse) from accidental intravascular injection or overdose
- Methemoglobinemia (more commonly associated with prilocaine, but theoretically possible)
- Permanent nerve damage (extremely rare, estimated at 1 in 26,000 to 1 in 785,000 injections)
It is important to distinguish between side effects of the local anesthetic agent and the common psychogenic reactions that occur during dental treatment. Anxiety, hyperventilation, vasovagal syncope (fainting), and panic attacks are frequently observed during dental procedures and are not caused by the local anesthetic itself, although they are often attributed to it by patients. These reactions are managed by positioning the patient appropriately (Trendelenburg position for syncope), providing reassurance, and ensuring adequate ventilation.
Persistent paresthesia (altered sensation lasting beyond the expected duration of anesthesia) is a known but uncommon complication of dental local anesthetic injections. The incidence is estimated at approximately 1 in 26,000 to 1 in 785,000 inferior alveolar nerve blocks. In most cases, the altered sensation resolves spontaneously within days to weeks, but in rare instances it may persist for months or become permanent. The risk is highest with the inferior alveolar nerve block and lingual nerve block techniques. While this complication has been reported with all dental local anesthetics, some studies suggest a slightly higher incidence with articaine 4% compared to other agents, though this remains controversial.
If you experience any side effects that concern you, particularly prolonged numbness, signs of an allergic reaction (rash, swelling, difficulty breathing), or symptoms suggesting systemic toxicity (dizziness, confusion, seizures, chest pain), contact your dentist or seek emergency medical care immediately.
How Should You Store Carbocain Dental?
Proper storage of Carbocain dental is essential to maintain the chemical stability, sterility, and efficacy of the medication. Local anesthetic solutions can degrade when exposed to extreme temperatures, light, or contamination, potentially leading to reduced anesthetic efficacy or, in rare cases, adverse reactions from degradation products.
The recommended storage conditions for Carbocain dental are:
- Temperature: Store at room temperature between 15°C and 25°C (59°F to 77°F). Do not freeze. Freezing can cause the glass cartridge to crack and can alter the chemical properties of the solution. Do not expose to temperatures above 25°C for prolonged periods.
- Light protection: Store in the original packaging to protect from light. Mepivacaine solutions should not be exposed to prolonged direct sunlight or fluorescent lighting, which can accelerate degradation.
- Sterility: Dental cartridges are supplied sterile and are intended for single use only. Do not autoclave or resterilize the cartridges, as this can compromise both the cartridge integrity and the chemical stability of the solution. Partially used cartridges must be discarded.
- Inspection before use: Visually inspect the cartridge before use. The solution should be clear and colorless. Do not use if the solution appears discolored, cloudy, or contains visible particles. Check the cartridge for cracks, chips, or damage to the rubber stopper or diaphragm. Do not use if the expiry date has passed.
Dental practitioners should maintain proper stock rotation (first-in, first-out) to ensure that older cartridges are used before newer ones. Expired or damaged cartridges should be disposed of in accordance with local pharmaceutical waste regulations. Keep out of the reach and sight of children. Patients do not typically handle or store this medication, as it is administered directly in the dental office.
What Does Carbocain Dental Contain?
Understanding the full composition of Carbocain dental is important for identifying potential allergens and for patients with known sensitivities to specific excipients. The formulation is deliberately simple, which reduces the number of potential allergens.
Active ingredient:
- Mepivacaine hydrochloride 30 mg/ml (3%). Mepivacaine hydrochloride is a white crystalline powder with a molecular weight of 282.81 g/mol and a pKa of 7.6. The relatively low pKa (closer to physiological pH of 7.4) compared to other local anesthetics contributes to the rapid onset of action, as a larger proportion of the drug exists in the un-ionized (lipophilic) form that can penetrate nerve membranes.
Excipients (inactive ingredients):
- Sodium chloride: Added to make the solution isotonic (the same osmolarity as body fluids), which reduces pain on injection and prevents tissue irritation.
- Water for injections: The solvent for the active ingredient and excipients. Pharmaceutical-grade water meeting strict purity standards.
- Sodium hydroxide and/or hydrochloric acid: Used for pH adjustment to approximately 4.5–6.8, optimizing the stability of the solution.
What this formulation does NOT contain:
- No vasoconstrictor (no epinephrine, levonordefrin, or felypressin)
- No preservatives (no methylparaben, which was historically used in multi-dose vials and was associated with allergic reactions in some patients)
- No sulfites (sulfites such as sodium metabisulfite are added to preserve epinephrine in vasoconstrictor-containing formulations, and can cause allergic reactions in sulfite-sensitive patients, particularly those with asthma)
- No latex in the cartridge components (important for patients with latex allergy)
The cartridge itself is made of Type I borosilicate glass, with a rubber stopper at one end and a rubber diaphragm at the other end. The rubber components are typically made of bromobutyl rubber and do not contain natural rubber latex, although dental practitioners should verify this with the specific manufacturer's product information, as formulations may vary by manufacturer and country.
Frequently Asked Questions About Carbocain Dental
Carbocain dental (mepivacaine 30 mg/ml) is a local anesthetic used exclusively in dentistry to provide pain relief during dental procedures. It is administered by injection into the gum tissue or around dental nerves to numb a specific area of the mouth. Common procedures where it is used include fillings, tooth extractions, crown preparations, root canal treatments, and gum surgery. Because this formulation does not contain a vasoconstrictor (such as epinephrine), it is particularly suitable for patients with cardiovascular conditions, uncontrolled hypertension, or those taking certain medications that interact with vasoconstrictors.
The duration of numbness depends on the injection technique used. For infiltration anesthesia (injection near individual teeth), pulpal (tooth) numbness typically lasts about 20 minutes, while soft tissue numbness (lip, cheek, tongue) may persist for 2 to 3 hours. For nerve block anesthesia (injection near major nerve trunks), pulpal numbness may last 40 to 60 minutes, with soft tissue numbness lasting up to 3 to 5 hours. The duration is generally shorter than with local anesthetic formulations containing a vasoconstrictor like epinephrine, which is actually an advantage for short procedures as patients regain normal sensation more quickly.
Dental treatment with local anesthesia is generally considered safe during pregnancy when necessary, according to guidelines from the American Dental Association (ADA) and the American College of Obstetricians and Gynecologists (ACOG). The second trimester is generally the preferred time for elective dental procedures. Mepivacaine does cross the placental barrier, so the lowest effective dose should always be used. However, Carbocain dental is specifically not recommended for obstetric paracervical block due to the risk of fetal bradycardia at the higher doses used in that context. For routine dental procedures, the risk from untreated dental infections generally outweighs the small risk from the local anesthetic itself.
The 3% mepivacaine formulation (Carbocain dental) is intentionally designed without a vasoconstrictor. Mepivacaine is unique among commonly used dental local anesthetics because it possesses inherent mild vasoconstrictive properties, meaning it can provide adequate anesthesia for short procedures without the need for added epinephrine. This makes it the formulation of choice for patients in whom epinephrine is contraindicated or undesirable, including those with severe cardiovascular disease, uncontrolled hypertension, hyperthyroidism, pheochromocytoma, sulfite allergy, or patients taking tricyclic antidepressants, MAO inhibitors, or non-selective beta-blockers. The trade-off is a shorter duration of anesthesia compared to formulations containing a vasoconstrictor.
Yes, Carbocain dental can be used in children over 3 years of age, but the dose must be carefully calculated based on the child's body weight. The maximum recommended dose for children is 3 mg/kg. Since each standard cartridge contains 54 mg of mepivacaine, a 20 kg child should receive no more than 60 mg (approximately 1.1 cartridges). The shorter duration of soft tissue numbness with this formulation is actually advantageous in pediatric patients, as it reduces the risk of self-inflicted lip and tongue biting injuries that commonly occur while the area is still numb. Parents should be advised to supervise their child until sensation has fully returned.
If numbness persists significantly beyond the expected duration (more than 4–6 hours after the injection), or if you experience altered sensation such as persistent tingling, burning, or loss of feeling in the lip, tongue, or chin, contact your dental practitioner. In most cases, prolonged numbness resolves on its own within a few days to weeks. Persistent paresthesia (altered sensation lasting more than 8 weeks) is rare but should be evaluated by your dentist or referred to an oral surgeon or neurologist. Warm compresses to the area may help increase blood flow and potentially speed the return of sensation, but there is no specific treatment to reverse the effect of local anesthetics other than waiting for the drug to be naturally metabolized.
References
- European Medicines Agency (EMA). Mepivacaine Summary of Product Characteristics. Updated 2025. Available at: www.ema.europa.eu
- Becker DE, Reed KL. Local Anesthetics: Review of Pharmacological Considerations. Anesthesia Progress. 2012;59(2):90-102. doi:10.2344/0003-3006-59.2.90
- American Dental Association (ADA). ADA Clinical Practice Guidelines: Local Anesthesia in Dentistry. Updated 2024. Available at: www.ada.org
- Malamed SF. Handbook of Local Anesthesia. 7th Edition. Elsevier; 2020.
- American Academy of Pediatric Dentistry (AAPD). Guideline on Use of Local Anesthesia for Pediatric Dental Patients. Pediatric Dentistry. 2023;45(6):Reference Manual.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023. Geneva: World Health Organization.
- Neal JM, Barrington MJ, Fettiplace MR, et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity. Regional Anesthesia & Pain Medicine. 2018;43(2):113-123. doi:10.1097/AAP.0000000000000720
- Pogrel MA, Thamby S. Permanent Nerve Involvement Resulting from Inferior Alveolar Nerve Blocks. Journal of the American Dental Association. 2000;131(7):901-907. doi:10.14219/jada.archive.2000.0308
- Garisto GA, Gaffen AS, Lawrence HP, et al. Occurrence of Paresthesia After Dental Local Anesthetic Administration in the United States. Journal of the American Dental Association. 2010;141(7):836-844. doi:10.14219/jada.archive.2010.0281
- British National Formulary (BNF). Mepivacaine Hydrochloride. National Institute for Health and Care Excellence (NICE). Updated 2025. Available at: bnf.nice.org.uk
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in dentistry, oral surgery, and clinical pharmacology
Medical Review
iMedic Medical Review Board – Independent panel of specialists following WHO, EMA, FDA, and ADA guidelines
Evidence Standard
Level 1A – Based on systematic reviews, randomized controlled trials, and established clinical guidelines
Independence
No pharmaceutical funding – Independent medical editorial content with no commercial conflicts of interest
This article was last reviewed on . All medical information is based on current international guidelines and peer-reviewed research. For the full editorial policy, see our editorial standards.